Growth Metrics

Pacific Biosciences Of California (PACB) Total Debt (2016 - 2023)

Pacific Biosciences Of California has reported Total Debt over the past 13 years, most recently at $96.2 million for Q3 2023.

  • Quarterly results put Total Debt at $96.2 million for Q3 2023, changed N/A from a year ago — trailing twelve months through Sep 2023 was $96.2 million (changed N/A YoY), and the annual figure for FY2022 was $172.6 million, up 4316.43%.
  • Total Debt for Q3 2023 was $96.2 million at Pacific Biosciences Of California, down from $186.3 million in the prior quarter.
  • Over the last five years, Total Debt for PACB hit a ceiling of $186.3 million in Q2 2023 and a floor of $3.9 million in Q4 2021.
  • Median Total Debt over the past 4 years was $134.4 million (2022), compared with a mean of $109.9 million.
  • Biggest five-year swings in Total Debt: grew 7.78% in 2019 and later soared 4316.43% in 2022.
  • Pacific Biosciences Of California's Total Debt stood at $15.8 million in 2019, then plummeted by 75.27% to $3.9 million in 2021, then soared by 4316.43% to $172.6 million in 2022, then crashed by 44.27% to $96.2 million in 2023.
  • The last three reported values for Total Debt were $96.2 million (Q3 2023), $186.3 million (Q2 2023), and $184.4 million (Q1 2023) per Business Quant data.